OCGN stock news · Ocugen, Inc.

Stories about Ocugen, Inc. (OCGN) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for OCGN

Follow Ocugen, Inc. (OCGN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Free on the App Store and Google Play, or on the web.

Nov 4, 2026, 8:30 AM ET · Market
Ocugen shared its financial results for the quarter ending September 30, 2026, and will hold a call to discuss them.
Neutral
Ocugen announced results for the quarter ended September 30, 2026, but this text gives no figures. It does not show a clear change in the company's outlook.
Oct 15, 2026, 8:09 AM ET · Market
Ocugen, Inc. shares important information in a filing with the SEC.
Neutral
Ocugen filed a report describing an investor presentation it plans to post and use. The filing gives no business results or new plans, so its outlook is unchanged.
Sep 8, 2026, 6:09 PM ET · Trial
Ocugen, Inc. shares news about starting a Phase 3 trial for its eye treatment OCU410.
Neutral
Ocugen started Phase 3 dosing and has RMAT status, but a DMC interim note raised a negative signal; I read the news as balanced and not shifting the company's outlook.